Cargando…

The effect of single course high dose dexamethasone on CD28/CTLA-4 balance in the treatment of patients with newly diagnosed primary immune thrombocytopenia

To evaluate the effect of a single course of high dose dexamethasone (HD-DXM) on CD28 and CTLA-4 expression in patients with newly-diagnosed primary immune thrombocytopenia (ITP). Twenty-8 ITP patients (18 females and 10 males, age range 18–65 years, median age 38.5 years) enrolled in this study and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Xinhong, Yasen, Halida, Zhao, Fang, Wang, Lei, Sun, Mingling, Pang, Nannan, Wang, Xiujuan, Zhang, Ying, Ding, Jianbing, Ma, Xiumin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962720/ https://www.ncbi.nlm.nih.gov/pubmed/26211942 http://dx.doi.org/10.1080/21645515.2015.1059975

Ejemplares similares

PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients
por: Wu, Die, et al.
Publicado: (2019)

Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2012)

The Efficacy of High-Dose Dexamethasone vs. Other Treatments for Newly Diagnosed Immune Thrombocytopenia: A Meta-Analysis
por: Xiao, Qirong, et al.
Publicado: (2021)

PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
por: Mingot Castellano, M. E., et al.
Publicado: (2022)

Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
por: Ville, Simon, et al.
Publicado: (2015)

Clinical efficacy of high-dose dexamethasone with sequential prednisone maintenance therapy for newly diagnosed adult immune thrombocytopenia in a real-world setting
por: Xu, Jin, et al.
Publicado: (2021)

Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia
por: Grainger, John D., et al.
Publicado: (2021)

Adolescents and young adults with newly diagnosed primary immune thrombocytopenia
por: Schifferli, Alexandra, et al.
Publicado: (2023)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes
Publicado: (1992)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Blockade Accelerates the Acute Rejection of Cardiac Allografts in CD28-deficient Mice: CTLA4 Can Function Independently of CD28
por: Lin, Hua, et al.
Publicado: (1998)

Regulatory and Memory B Lymphocytes in Children With Newly Diagnosed Immune Thrombocytopenia
por: Zahran, Asmaa M., et al.
Publicado: (2017)

A case of newly diagnosed immune thrombocytopenia in the COVID-19 era
por: Clerici, Bianca, et al.
Publicado: (2020)

Doppler ultrasound screening in patients with newly diagnosed heparin-induced thrombocytopenia
por: Harris, Elyse I., et al.
Publicado: (2021)

Newly Diagnosed Idiopathic Thrombocytopenia Post COVID-19 Vaccine Administration
por: Idogun, Precious O, et al.
Publicado: (2021)

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
Publicado: (1995)

Thrombocytopenia Caused by Dexamethasone in a Patient with Colorectal Cancer
por: Taguchi, Ryosuke, et al.
Publicado: (2020)

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years
por: Yokoyama, Akihiro, et al.
Publicado: (2022)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Dexamethason senkt die 28-Tage-Mortalität
por: Diener, Hans-Christoph
Publicado: (2020)

Contributions of T Lymphocyte Abnormalities to Therapeutic Outcomes in Newly Diagnosed Patients with Immune Thrombocytopenia
por: Zhao, Zhenhua, et al.
Publicado: (2015)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Expression patterns of CD28 and CTLA‐4 in early, chronic, and untreated rheumatoid arthritis
por: García‐Chagollán, Mariel, et al.
Publicado: (2020)

Hypovitaminosis D Influences the Clinical Presentation of Immune Thrombocytopenia in Children with Newly Diagnosed Disease
por: Petrovic, Davor, et al.
Publicado: (2019)

Thrombocytopenia in the Course of COVID-19 Infection
por: Lorenzo-Villalba, Noel, et al.
Publicado: (2020)

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
por: Bouwhuis, Marna G., et al.
Publicado: (2009)

Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion
por: Sekulic, Aleksandar, et al.
Publicado: (2015)

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2018)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis
por: Rosenbaum, Cara A., et al.
Publicado: (2022)

High-Dose Dexamethasone Alters the Increase in Interleukin-16 Level in Adult Immune Thrombocytopenia
por: Wang, Xinru, et al.
Publicado: (2019)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
por: Crusoe, Edvan De Queiroz, et al.
Publicado: (2020)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Platelet to Lymphocyte Ratio and Glucocorticoid Resistance in Newly Diagnosed Primary Immune Thrombocytopenia: A Retrospective Cohort Study
por: Wang, Lin-Hui, et al.
Publicado: (2019)

Prolonged Disease Course of COVID-19 in a Patient with CTLA-4 Haploinsufficiency
por: Hoffman, T. W., et al.
Publicado: (2023)

The Th17/Treg balance and the expression of related cytokines in Uygur cervical cancer patients
por: Chen, Zhifang, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_joakj2sm957uudqqecgtf6lnr8